For many years, researchers have sought different categories of biomarkers such as cell surface antigens (neutrophil CD64), calprotectin, gut-specific proteins (intestinal fatty acid binding protein, I-FABP), and gut micorbiomes in plasma, urine, and stool samples.[8–11] However, to date, there is no ideal biomarker for screening and diagnosing NEC, or predicting the severity of disease and guiding therapeutic management. The gene discussed is FABP2; the disease is necrotizing enterocolitis.